X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs SANOFI INDIA - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON SANOFI INDIA BIOCON /
SANOFI INDIA
 
P/E (TTM) x 41.0 34.9 117.5% View Chart
P/BV x 7.1 6.0 119.0% View Chart
Dividend Yield % 0.2 1.5 11.2%  

Financials

 BIOCON    SANOFI INDIA
EQUITY SHARE DATA
    BIOCON
Mar-18
SANOFI INDIA
Dec-18
BIOCON /
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,1886,840 17.4%   
Low Rs3054,630 6.6%   
Sales per share (Unadj.) Rs68.71,203.1 5.7%  
Earnings per share (Unadj.) Rs7.6165.3 4.6%  
Cash flow per share (Unadj.) Rs14.0209.9 6.7%  
Dividends per share (Unadj.) Rs1.0084.00 1.2%  
Dividend yield (eoy) %0.11.5 9.1%  
Book value per share (Unadj.) Rs86.3963.6 9.0%  
Shares outstanding (eoy) m600.0023.03 2,605.3%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.94.8 227.9%   
Avg P/E ratio x98.934.7 284.9%  
P/CF ratio (eoy) x53.427.3 195.5%  
Price / Book Value ratio x8.66.0 145.3%  
Dividend payout %13.250.8 26.1%   
Avg Mkt Cap Rs m447,900132,078 339.1%   
No. of employees `0006.13.3 186.3%   
Total wages/salary Rs m9,3114,068 228.9%   
Avg. sales/employee Rs Th6,705.88,393.8 79.9%   
Avg. wages/employee Rs Th1,514.21,232.4 122.9%   
Avg. net profit/employee Rs Th736.91,153.0 63.9%   
INCOME DATA
Net Sales Rs m41,23427,708 148.8%  
Other income Rs m2,062897 229.9%   
Total revenues Rs m43,29628,605 151.4%   
Gross profit Rs m8,2916,235 133.0%  
Depreciation Rs m3,8511,027 375.0%   
Interest Rs m6157 8,785.7%   
Profit before tax Rs m5,8876,098 96.5%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5692,292 68.5%   
Profit after tax Rs m4,5313,806 119.0%  
Gross profit margin %20.122.5 89.4%  
Effective tax rate %26.737.6 70.9%   
Net profit margin %11.013.7 80.0%  
BALANCE SHEET DATA
Current assets Rs m41,48615,922 260.6%   
Current liabilities Rs m21,4136,235 343.4%   
Net working cap to sales %48.735.0 139.2%  
Current ratio x1.92.6 75.9%  
Inventory Days Days6464 100.5%  
Debtors Days Days9421 451.3%  
Net fixed assets Rs m50,6617,539 672.0%   
Share capital Rs m3,000230 1,304.3%   
"Free" reserves Rs m48,80821,962 222.2%   
Net worth Rs m51,80822,192 233.5%   
Long term debt Rs m17,8980-   
Total assets Rs m99,89729,839 334.8%  
Interest coverage x10.6872.1 1.2%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.40.9 44.5%   
Return on assets %5.212.8 40.3%  
Return on equity %8.717.2 51.0%  
Return on capital %9.627.5 35.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,0587,587 158.9%   
Fx outflow Rs m7,3487,145 102.8%   
Net fx Rs m4,710442 1,065.6%   
CASH FLOW
From Operations Rs m6,6213,739 177.1%  
From Investments Rs m-6,840-731 935.7%  
From Financial Activity Rs m-2,397-1,972 121.6%  
Net Cashflow Rs m-2,6121,036 -252.1%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 60.4 34.1%  
Indian inst/Mut Fund % 8.4 14.4 58.3%  
FIIs % 10.7 14.6 73.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.5 189.5%  
Shareholders   109,995 15,184 724.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   VENUS REMEDIES  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  SHASUN PHARMA  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)

Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.

Related Views on News

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Apr 18, 2019 (Close)

TRACK BIOCON

BIOCON - DIVIS LABORATORIES COMPARISON

COMPARE BIOCON WITH

MARKET STATS